{"entity":{"id":"nct05987644","kind":"trial","name":"Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements","aka":["DURABLE"],"tldr":"A phase 1/2 trial of alectinib in lung cancer, run by Joshua Palmer, now recruiting.","summary":"Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements is a phase 1/2, randomised interventional study registered as NCT05987644 by Joshua Palmer, with a registry enrolment figure of 56 participants, started 2024-03-07 and due to reach its primary completion in 2028-02-28. Interventions recorded: Alectinib; Stereotactic Radiosurgery. Conditions listed: Lung Cancer; NSCLC; Brain Metastases. Primary outcome: Phase 2: Neurological status and control of CNS disease at 12 months compared to alectinib plus SRS in patients with ≤15 CNS metastases; Phase 1b: Safety and Feasibility. Lung eligibility wording from the registry: \"Histological or cytological confirmation of Stage IV (per AJCC 8th edition) non-small cell lung cancer (NSCLC)\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT05987644","url":"https://clinicaltrials.gov/study/NCT05987644"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["alk-positive-nsclc"],"sections":[],"technologies":["kinase-inhibitors","sbrt"],"targets":[],"drugs":["alectinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05987644","phase":"1/2","setting":"DURABLE: Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and rEarrangements","sponsor":"Joshua Palmer","enrolled":56,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05987644/","neighbours":{"cancer":[{"id":"alk-positive-nsclc","kind":"cancer","name":"ALK-positive non-small-cell lung cancer","route":"/cancers/alk-positive-nsclc/"}],"technology":[{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"alectinib","kind":"drug","name":"Alectinib","route":"/drugs/alectinib/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}